Other Events ·
Alto Neuroscience reports $244.2M in cash and plans to accelerate ALTO-207 clinical development with additional Phase 3 trial for treatment-resistant depression
ANROAlto Neuroscience, Inc.
Alto Neuroscience, Inc. announced that its estimated cash, cash equivalents, and restricted cash totaled approximately $244.2 million as of June 30, 2026. The company also announced plans to accelerate and expand the clinical development of its ALTO-207 program, which includes conducting an additional Phase 3 trial for treating treatment-resistant depression. Alto Neuroscience, Inc. is a biotechnology company focused on neurological disorders.